Valuation : EnteroMedics Inc

Market Cap 1.45Cr 1.25Cr 1.18Cr 1.07Cr 2.01Cr 138.13Cr 2.02Cr 14Cr 5.39Cr 70Cr 5.43Cr 5.31Cr 222.05Cr P/E 2026 *
-3.61x
P/E 2027 * -2.58x
Enterprise Value 1.45Cr 1.25Cr 1.18Cr 1.07Cr 2.01Cr 138.13Cr 2.02Cr 14Cr 5.39Cr 70Cr 5.43Cr 5.31Cr 222.05Cr EV / Sales 2026 *
108x
EV / Sales 2027 * 72.3x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 1L 1L 1L 98.59T 2L 1.27Cr 2L 12.92L 5L 64.8L 5L 5L 2.05Cr 2L 2L 2L 1L 3L 1.91Cr 3L 19.38L 7L 97.21L 8L 7L 3.07Cr
Net income -40L -34.46L -32.63L -29.58L -55.49L -38Cr -55.77L -3.88Cr -1.49Cr -19Cr -1.5Cr -1.47Cr -61Cr -78.46L -67.6L -64.01L -58.02L -1.09Cr -75Cr -1.09Cr -7.6Cr -2.92Cr -38Cr -2.95Cr -2.88Cr -120.5Cr
Net Debt - -
Logo EnteroMedics Inc
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Employees
-
Sector
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!